Key result
Higher plasma levels of GPX4 were a protective factor for major adverse cardiac events (OR 0.976), whereas higher Neu5Ac levels were an independent risk factor (OR 1.001) in patients with acute coronary syndrome.
Why the study?
To investigate the correlation between plasma GPX4 and Neu5Ac levels with clinical risk stratification and outcomes in ACS patients.
Do plasma GPX4 and Neu5Ac levels correlate with clinical risk stratification and prognosis in patients with acute coronary syndrome?
Observational (n=413)
No
Do plasma GPX4 and Neu5Ac levels correlate with clinical risk stratification and prognosis in patients with acute coronary syndrome?
Odds Ratio: 0.976 (95% CI 0.955–0.997)
p-value: p=0.026
May support ACS risk stratification with GPX4/Neu5Ac; leaves open incremental value beyond TIMI scores in prospective validation.
OBJECTIVES: To investigate the correlation between plasma glutathione peroxidase 4 (GPX4) and N-acetyl-neuraminic acid (Neu5Ac) with clinical risk stratification and outcomes of acute coronary syndrome (ACS) patients. METHODS: Between October 2018 and July 2019, 413 patients that were scheduled for coronary angiography were enrolled in this prospective study at the First Affiliated Hospital of Bengbu Medical College, Bengbu, China. Patients were divided into control and ACS groups. Patients with ACS were divided into 3 risk levels based on their thrombolysis in myocardial infarction risk score. After discharge, ACS patients were followed for the incidence of major adverse cardiac events (MACEs). For the analysis of cumulative endpoint event occurrences, the Kaplan-Meier method was applied. RESULTS: The ACS group had lower plasma GPX4 but higher Neu5Ac levels than the control group. There was a greater increase in plasma Neu5Ac in the high-risk group when compared with the medium-risk and low-risk groups, while GPX4 levels were higher in the low-risk group. The MACEs group had higher plasma Neu5Ac but lower GPX4 levels than the non-MACEs group. The plasma Neu5Ac was an independent risk factor but GPX4 was a protective factor for MACEs. CONCLUSION: Glutathione peroxidase 4 and Neu5Ac levels in plasma can be used to diagnose, stratify risks, and predict long-term outcomes in patients with ACS.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) conducted an observational in Acute coronary syndrome (n=413). Plasma glutathione peroxidase 4 (GPX4) and N-acetylneuraminic acid (Neu5Ac) levels vs. Control group (non-ACS) or varying biomarker levels was evaluated on Major adverse cardiac events (MACEs) (OR 0.976, 95% CI 0.955-0.997, p=0.026). Higher plasma levels of GPX4 were a protective factor for major adverse cardiac events (OR 0.976), whereas higher Neu5Ac levels were an independent risk factor (OR 1.001) in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: